AI-driven CRM puts pharma in make-or-break shift: Accenture exec
NEW YORK, UNITED STATES — Healthcare providers in the United States may soon feel ripple effects from a major shift underway in the pharmaceutical industry, as artificial intelligence (AI) reshapes how drugmakers engage physicians, hospitals, and health systems.
In a thought leadership article, Gro Blindheim warns that AI-powered customer relationship management (CRM) is at a make-or-break moment for pharma, with implications for how clinicians receive information, support, and follow-up from drug companies. Blindheim is a Managing Director at Accenture with over 28 years of experience in professional services across business advisory, IT consulting, and outsourcing.
Pharmaceutical firms are under pressure to modernize engagement as costs rise and expectations for relevance and speed grow.
According to Accenture research cited in the article, “up to 70% of impactable sales are driven by field engagement,” underscoring the continued importance of in-person interactions between representatives and clinicians.
Yet many reps are hampered by outdated systems, with “only 1 in 4 field teams” feeling fully supported by their CRM tools.
For healthcare providers, that gap often translates into fragmented conversations, repetitive outreach, and delayed access to useful clinical or product insights.
How AI pharma CRM could change provider engagement
Blindheim said that AI-enabled CRM could change that dynamic by helping reps arrive better prepared and more responsive.
“We’re reaching a point where a rep can walk into a meeting with a single, AI-curated brief that merges medical insights, market trends and prior interactions,” Blindheim stated.
In practice, that could mean fewer generic sales pitches and more tailored discussions that align with a hospital’s patient mix, formulary decisions, or care pathways.
“During meetings in-the-moment guidance can surface compliant content and suggest pivots based on real-time signals while after the visit, post-call follow-up triggers digital sequences that actually land,” Blindheim explained.
For hospitals and clinics, the promise is continuity: interactions that build on previous conversations rather than restarting them.
Blindheim noted that AI can “connect what happens in a call to what happens across digital channels,” making engagement “sharper, timelier and more relevant.”
Organizational change needed to unlock AI’s value
Blindheim cautions that technology alone will not deliver results.
“AI alone won’t deliver the reinvention the industry needs,” Blindheim said, stressing that “the real shift is organizational.”
That includes redesigning workflows, governance, and roles so AI acts as “connective tissue across teams rather than a bolt-on tool.”
For providers, that organizational shift matters. Better coordination between pharma medical affairs, marketing, and field teams could reduce mixed messages and improve compliance. Embedded guardrails could also “reduce risk while speeding execution.”
Blindheim frames the moment as urgent. Pharma companies face “a once-in-a-decade opportunity” to move past fragmented engagement models.
Those that succeed, it says, will deliver experiences that feel “personal, not programmatic.”
For U.S. health systems navigating workforce strain and information overload, that shift could make interactions with pharma more useful — or, if mishandled, more noise in an already crowded landscape.
